Ofloxacin 3 mg/mL Solution/ Drops
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Quinolone Antimicrobial class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- No — please don't do that. The ear drops and eye drops are different formulations made for very different tissues. Using ear drops in your eye could cause irritation or harm. If yo...
- I was given ofloxacin ear drops. Can I use them in my eye instead if I don't have the eye drops right now?
- The biggest ones to act on right away are tendon pain or a popping sensation (especially around the heel or shoulder), numbness or tingling in your hands or feet, and severe mental...
- What are the most serious side effects I should actually watch out for?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Ofloxacin — tap one for details:
Ofloxacin may be associated with lower levels of 11 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII F5UM2KM3W7
Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $1.268 | $6.34 / 5 ml |
| Medicaid paysCMS SDUD · 12 mo | $3.72 | $18.59 / 5 ml |
| Medicare drug plans payPart D · Q2 2026 | $1.98 | $9.88 / 5 ml |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Ofloxacin 3 mg/mL 64980-0515-01 | Rising | 1 bottle | $1.183 | AT | Availability likely | save 7% |
| Ofloxacin 3 mg/mL 65145-0142-01 | Caplin | 10 ml | $1.183 | AT | Availability likely | save 7% |
| ofloxacin 3 mg/mL 70756-0650-30 | Lifestar | 1 bottle | $1.183 | AT | Availability likely | save 7% |
| ofloxacin 3 mg/mL 00904-7434-05 | Major | 1 bottle | $1.268 | AT | Availability likely | — |
| Ofloxacin 3 mg/mLthis 24208-0434-05 | Bausch | 1 bottle | $1.268 | AT | Availability likely | — |
| Ofloxacin 3 mg/mL 60505-0560-00 | Apotex | 1 bottle | $1.268 | AT | Availability likely | — |
| Ofloxacin 3 mg/mL 65145-0141-01 | Caplin | 5 ml | $1.268 | AT | Availability likely | — |
| Ofloxacin 3 mg/mL 69315-0327-05 | Leading | 5 ml | $1.268 | AT | Availability likely | — |
| Ofloxacin 3 mg/mL 70069-0411-01 | Somerset | 1 bottle | $1.268 | AT | Availability likely | — |
| Ofloxacin 3 mg/mL 70512-0793-05 | SOLA | 1 bottle | $1.268 | AT | Availability likely | — |
| ofloxacin 3 mg/mL 70756-0607-30 | Lifestar | 1 bottle | $1.268 | AT | Availability likely | — |
| Ofloxacin 3 mg/mL 72485-0613-10 | ARMAS | 1 bottle | $1.268 | AT | Availability likely | — |
| ofloxacin 3 mg/mL 72603-0192-01 | NorthStar | 5 ml | $1.268 | AT | Availability likely | — |
| Ocuflox 3 mg/mL 11980-0779-05 | Allergan, | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 50090-1744-00 | A-S | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 50090-5186-00 | A-S | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 50090-5209-00 | A-S | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 50090-5425-00 | A-S | 1 bottle | — | AT | FDA listed | — |
| ofloxacin 3 mg/mL 50090-6794-00 | A-S | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 50090-7264-00 | A-S | 1 bottle | — | AT | FDA listed | — |
| ofloxacin 3 mg/mL 50090-7761-00 | A-S | 5 ml | — | AT | FDA listed | — |
| Ofloxacin ophthalmic 3 mg/mL 59390-0140-05 | Altaire | 5 ml | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 60760-0917-05 | St. | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 60760-0970-05 | ST. | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 63187-0268-05 | Proficient | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 63187-0662-05 | Proficient | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 63187-0734-05 | Proficient | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 68071-1607-05 | NuCare | 5 ml | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 68071-2254-05 | NuCare | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 68071-2265-01 | NuCare | 1 bottle | — | AT | FDA listed | — |
| ofloxacin 3 mg/mL 68071-3448-05 | NuCare | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 68071-3566-01 | NuCare | 1 bottle | — | AT | FDA listed | — |
| ofloxacin 3 mg/mL 68071-3919-05 | NuCare | 5 ml | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 68788-7693-05 | Preferred | 1 bottle | — | AT | FDA listed | — |
| ofloxacin 3 mg/mL 68788-8449-05 | Preferred | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 68788-8761-05 | Preferred | 1 bottle | — | AT | FDA listed | — |
| ofloxacin 3 mg/mL 70518-3710-00 | REMEDYREPACK | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 71205-0420-05 | Proficient | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin Ophth Soln 3 mg/mL 72189-0472-05 | Direct_Rx | 5 ml | — | AT | FDA listed | — |
| ofloxacin 3 mg/mL 82804-0101-05 | Proficient | 1 bottle | — | AT | FDA listed | — |
| Ofloxacin 3 mg/mL 70518-3573-00 | REMEDYREPACK | 1 bottle | — | AT | Discontinued | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 24208-0434-05 You're viewing this | 1 BOTTLE, DROPPER in 1 CARTON (24208-434-05) / 5 mL in 1 BOTTLE, DROPPER | $1.27 / mL | $6.34 | 2004-05-14 | Active |
| 24208-0434-10 | 1 BOTTLE, DROPPER in 1 CARTON (24208-434-10) / 10 mL in 1 BOTTLE, DROPPER | $1.18 / mL | $11.83 | 2004-05-14 | Active |
Per mL, this pack runs about 7% above the cheapest pack (NDC 24208-0434-10, $1.18 vs $1.27 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 87% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 24208-0434-05?
What NDC number is used to bill for this package of Ofloxacin 3 mg/mL Solution/ Drops?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION The recommended dosage regimen for the treatment of bacterial conjunctivitis is: Days 1 and 2 Instill one to two drops every two to four hours in the affected eye(s). Days 3 through 7 Instill one to two drops four times daily. The recommended dosage regimen for the treatment of bacterial corneal ulcer is: Days 1 and 2 Instill one to two drops into the affected eye every 30 minutes, while awake.
Awaken at approximately four and six hours after retiring and instill one to two drops. Days 3 through 7 to 9 Instill one to two drops hourly, while awake. Days 7 to 9 through Instill one to two drops, four times daily. treatment completion DO NOT
⛔ Contraindications ▾
CONTRAINDICATIONS Ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication ( see WARNINGS ).
⚠️ Warnings ▾
WARNINGS NOT FOR INJECTION. Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin.
Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug.
Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Ophthalmic Use The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain. Rare reports of dizziness and nausea have been received.
Refer to Warnings for additional adverse reactions. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🔄 Drug Interactions ▾
Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
🧒 Pediatric Use ▾
Pediatric Use Safety and effectiveness in infants below the age of one year have not been established. Quinolones, including ofloxacin, have been shown to cause arthropathy in immature animals after oral administration; however, topical ocular administration of ofloxacin to immature animals has not shown any arthropathy. There is no evidence that the ophthalmic dosage form of ofloxacin has any effect on weight bearing joints.
🧓 Geriatric Use ▾
Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Pharmacokinetics Serum, urine and tear concentrations of ofloxacin were measured in 30 healthy women at various time points during a ten-day course of treatment with ofloxacin ophthalmic solution. The mean serum ofloxacin concentration ranged from 0.4 ng/mL to 1.9 ng/mL. Maximum ofloxacin concentration increased from 1.1 ng/mL on day one to 1.9 ng/mL on day 11 after QID dosing for 10 1/2 days.
Maximum serum ofloxacin concentrations after ten days of topical ophthalmic dosing were more than 1000 times lower than those reported after standard oral doses of ofloxacin. Tear ofloxacin concentrations ranged from 5.7 to 31 mcg/g during the 40 minute period following the last dose on day 11. Mean tear concentration measured four hours after topical ophthalmic dosing was 9.2 mcg/g.
Corneal tissue concentrations of 4.4 mcg/mL were observed four hours after beginning topical ocular application of two drops of ofloxacin ophthalmic solution every 30 minutes. Ofloxacin was excreted in the urine primarily unmodified. Microbiology Ofloxacin has in vitro activity against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria.
Ofloxacin is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. Ofloxacin is thought to exert a bactericidal effect on susceptible bacterial cells by inhibiting DNA gyrase, an essential bacterial enzyme which is a critical catalyst in the duplication, transcription, and repair of bacterial DNA. Cross-resistance has been observed between ofloxacin and other fluoroquinolones.
There is generally no cross-resistance between ofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides. Ofloxacin has been shown to be active against most strains of the following organisms both in vitro and clinically, in conjunctival and/or corneal ulcer infections ( see INDICATIONS AND USAGE ). AEROBES, GRAM-POSITIVE: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae AEROBES, GRAM-NEGATIVE: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens* ANAEROBIC SPECIES: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections.
The safety and effectiveness of ofloxacin ophthalmic solution in treating ophthalmologic infections due to the following organisms have not been established in adequate and well-controlled clinical trials. Ofloxacin ophthalmic solution has been shown to be active in vitro against most strains of these organisms but the clinical significance in ophthalmologic infections is unknown. AEROBES, GRAM-POSITIVE: Enterococcus faecalis Listeria monocytogenes Staphylococcus capitis Staphylococcus hominus Staphylococcus simulans Streptococcus pyogenes AEROBES, GRAM-NEGATIVE: Acinetobacter calcoaceticus var. anitratus Acinetobacter calcoaceticus var. lwoffi Citrobacter diversus Citrobacter freundii Enterobacter aerogenes Enterobacter agglomerans Escherichia coli Haemophilus parainfluenzae Klebsiella oxytoca Klebsiella pneumoniae Moraxella (Branhamella) catarrhalis Moraxella lacunata Morganella morganii Neisseria gonorrhoeae Pseudomonas acidovorans Pseudomonas fluorescens Shigella sonnei OTHER: Chlamydia trachomatis Clinical Studies Conjunctivitis In a randomized, double-masked, multicenter clinical trial, ofloxacin ophthalmic solution was superior to its vehicle after 2 days of treatment in patients with conjunctivitis and positive conjunctival cultures.
Clinical outcomes for the trial demonstrated a clinical improvement rate of 86% (54/63) for the ofloxacin treated group versus 72% (48/67) for the placebo treated group after 2 days of therapy. Microbiological outcomes for the same clinical trial demonstrated an eradication rate for causative pathogens of 65% (41/63) for the ofloxacin treated group versus 25% (17/67) for the vehicle treated group after 2 days of therapy. Please note that microbiologic eradication doe…
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Ofloxacin ophthalmic solution, 0.3% is supplied sterile in plastic dropper bottles with tan caps in the following sizes: 5 mL NDC 24208-434-05 10 mL NDC 24208-434-10
📦 Storage and Handling ▾
NOTE: Store at 15°C to 25°C (59°F to 77°F). KEEP OUT OF REACH OF CHILDREN. FOR OPHTHALMIC USE ONLY. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2023 Bausch & Lomb Incorporated or its affiliates 9118306 (FOLDED) 9118206 (FLAT) Rev. 04/2023
📋 Description ▾
DESCRIPTION Ofloxacin ophthalmic solution, 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use. Chemical Name: (±)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7 H -pyrido[1,2,3- de ]-1,4- benzoxazine-6-carboxylic acid.
Contains: Active: ofloxacin 0.3% (3 mg/mL) Preservative: benzalkonium chloride (0.005%) Inactives: sodium chloride and purified water. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH. Ofloxacin ophthalmic solution is unbuffered and formulated with a pH of 6.4 (range - 6.0 to 6.8).
It has an osmolality of 300 mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure. chem
💬 Information for Patients ▾
Information for Patients Avoid contaminating the applicator tip with material from the eye, fingers or other source. Systemic quinolones, including ofloxacin, have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction.